Stockscreener 앱 받기
1.74
3.57%
0.06
시간 외 거래:
1.80
0.06
+3.45%
전일 마감가:
$1.68
열려 있는:
$1.69
하루 거래량:
288.66K
Relative Volume:
2.82
시가총액:
$54.55M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.6259
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
-33.33%
1개월 성능:
-67.23%
6개월 성능:
-75.53%
1년 성능:
-73.99%
1일 변동 폭
$1.62
$1.8998
1주일 범위
$1.56
$2.97
52주 변동 폭
$1.56
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.74 | 54.55M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks
Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance
H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com India
HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan
Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech
JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia
Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga
Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com
JMP maintains Acrivon stock with $17 target following update - Investing.com India
Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia
Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa
Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential - Investing.com
Citizens JMP reiterates Acrivon stock with $17 target - Investing.com
Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating - TipRanks
Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Thursday - Defense World
Acrivon Therapeutics to Host Corporate R&D Event to Provide - GlobeNewswire
Acrivon Unveils Next-Gen Cancer Platform: Key Updates from Leading Oncology Experts - StockTitan
Acrivon Therapeutics to Host Virtual R&D Event on March 25, 2025, Featuring Updates on ACR-368 and ACR-2316 - Nasdaq
Acrivon Therapeutics Names Adam Levy as CFO -March 17, 2025 at 05:36 am EDT - Marketscreener.com
(ACRV) Investment Report - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February - The AM Reporter
Acrivon Therapeutics appoints new CFO as predecessor steps down By Investing.com - Investing.com Australia
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7% - Defense World
Acrivon Therapeutics appoints new CFO as predecessor steps down - Investing.com India
Acrivon Therapeutics Appoints New Chief Financial Officer - TipRanks
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67 - Defense World
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On? - MSN
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts - Defense World
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):